Brady RO - Search Results

1

Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher disease.

Barton NW, Brady RO, Dambrosia JM, Doppelt SH, Hill SC, Holder CA, Mankin HJ, Murray GJ, Zirzow GC, Parker RI. Barton NW, et al. Among authors: brady ro. J Pediatr. 1992 Feb;120(2 Pt 1):277-80. doi: 10.1016/s0022-3476(05)80444-5. J Pediatr. 1992. PMID: 1735829

2

MRI of multiple platyspondyly in Gaucher disease: response to enzyme replacement therapy.

Hill SC, Parker CC, Brady RO, Barton NW. Hill SC, et al. Among authors: brady ro. J Comput Assist Tomogr. 1993 Sep-Oct;17(5):806-9. doi: 10.1097/00004728-199309000-00026. J Comput Assist Tomogr. 1993. PMID: 8370839

3

Analysis of the lipids of normal and Gaucher bone marrow.

Miller SP, Zirzow GC, Doppelt SH, Brady RO, Barton NW. Miller SP, et al. Among authors: brady ro. J Lab Clin Med. 1996 Apr;127(4):353-8. doi: 10.1016/s0022-2143(96)90183-3. J Lab Clin Med. 1996. PMID: 8656038

4

Enzyme replacement and gene therapy for Gaucher's disease.

Brady RO, Barton NW. Brady RO, et al. Lipids. 1996 Mar;31 Suppl:S137-9. doi: 10.1007/BF02637065. Lipids. 1996. PMID: 8729108

5

Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.

Schiffmann R, Heyes MP, Aerts JM, Dambrosia JM, Patterson MC, DeGraba T, Parker CC, Zirzow GC, Oliver K, Tedeschi G, Brady RO, Barton NW. Schiffmann R, et al. Among authors: brady ro. Ann Neurol. 1997 Oct;42(4):613-21. doi: 10.1002/ana.410420412. Ann Neurol. 1997. PMID: 9382473 Clinical Trial.

6

Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease.

Brady RO, Murray GJ, Oliver KL, Leitman SF, Sneller MC, Fleisher TA, Barton NW. Brady RO, et al. Pediatrics. 1997 Dec;100(6):E11. doi: 10.1542/peds.100.6.e11. Pediatrics. 1997. PMID: 9382912

7

Delivery, distribution, and neuronal uptake of exogenous mannose-terminal glucocerebrosidase in the intact rat brain.

Zirzow GC, Sanchez OA, Murray GJ, Brady RO, Oldfield EH. Zirzow GC, et al. Among authors: brady ro. Neurochem Res. 1999 Feb;24(2):301-5. doi: 10.1023/a:1022578424693. Neurochem Res. 1999. PMID: 9972879

8

Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.

Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW. Altarescu G, et al. Among authors: brady ro. Blood Cells Mol Dis. 2000 Aug;26(4):285-90. doi: 10.1006/bcmd.2000.0310. Blood Cells Mol Dis. 2000. PMID: 11042029 Clinical Trial.

9

The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease.

Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC, Brady RO, Barton NW, Schiffmann R. Altarescu G, et al. Among authors: brady ro. J Pediatr. 2001 Apr;138(4):539-47. doi: 10.1067/mpd.2001.112171. J Pediatr. 2001. PMID: 11295718

10

Neurologic complications of nonneuronopathic Gaucher's disease.

Grewal RP, Doppelt SH, Thompson MA, Katz D, Brady RO, Barton NW. Grewal RP, et al. Among authors: brady ro. Arch Neurol. 1991 Dec;48(12):1271-2. doi: 10.1001/archneur.1991.00530240075025. Arch Neurol. 1991. PMID: 1845033

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

541 results

Search Page

Filters